Esperion to Report First Quarter 2025 Financial Results on May 6
Esperion (NASDAQ: ESPR) has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025, before market opening. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.
Esperion is a commercial stage biopharmaceutical company that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial, which included nearly 14,000 patients.
The company is also advancing its next generation program focusing on ATP citrate lyase inhibitors (ACLYi), utilizing new insights into structure and function for rational drug design of highly potent and specific inhibitors with allosteric mechanisms.
Esperion (NASDAQ: ESPR) ha annunciato che pubblicherà i suoi risultati finanziari del primo trimestre 2025 martedì 6 maggio 2025, prima dell'apertura dei mercati. L'azienda terrà una webcast alle 8:00 ET per discutere i risultati e fornire aggiornamenti aziendali.
Esperion è una società biofarmaceutica in fase commerciale che sviluppa e commercializza farmaci orali, una volta al giorno, non statinici, approvati dalla FDA per pazienti con malattie cardiovascolari e livelli elevati di LDL-C. I loro farmaci sono supportati dallo studio CLEAR Cardiovascular Outcomes Trial, che ha coinvolto quasi 14.000 pazienti.
L'azienda sta inoltre portando avanti il suo programma di nuova generazione focalizzato sugli inibitori dell'ATP citrato liasi (ACLYi), sfruttando nuove conoscenze sulla struttura e funzione per la progettazione razionale di inibitori altamente potenti e specifici con meccanismi allosterici.
Esperion (NASDAQ: ESPR) ha anunciado que publicará sus resultados financieros del primer trimestre de 2025 el martes 6 de mayo de 2025, antes de la apertura del mercado. La compañía realizará una transmisión en línea a las 8:00 a.m. ET para hablar sobre los resultados y ofrecer actualizaciones comerciales.
Esperion es una empresa biofarmacéutica en etapa comercial que desarrolla y comercializa medicamentos orales, de una sola dosis diaria, no estatinas, aprobados por la FDA para pacientes con enfermedades cardiovasculares y niveles elevados de LDL-C. Sus medicamentos cuentan con el respaldo del estudio CLEAR Cardiovascular Outcomes Trial, que incluyó a casi 14,000 pacientes.
La compañía también está avanzando en su programa de próxima generación centrado en inhibidores de ATP citrato liasa (ACLYi), utilizando nuevos conocimientos sobre estructura y función para el diseño racional de inhibidores altamente potentes y específicos con mecanismos alostéricos.
에스페리온 (NASDAQ: ESPR)은 2025년 5월 6일 화요일 장 개장 전에 2025년 1분기 재무 실적을 발표할 예정입니다. 회사는 오전 8시(동부시간)에 웹캐스트를 통해 실적을 논의하고 사업 업데이트를 제공할 것입니다.
에스페리온은 심혈관 질환 및 LDL-C 수치가 높은 환자를 위한 FDA 승인 경구용 비스타틴제 일일 1회 복용 약물을 개발 및 상용화하는 상업 단계의 바이오제약 회사입니다. 이들의 약물은 약 14,000명의 환자가 참여한 CLEAR 심혈관 결과 시험에 의해 뒷받침됩니다.
회사는 또한 ATP 시트르산 분해효소 억제제(ACLYi)에 초점을 맞춘 차세대 프로그램을 진행 중이며, 구조와 기능에 대한 새로운 통찰을 활용해 알로스테릭 메커니즘을 가진 매우 강력하고 특이적인 억제제를 합리적으로 설계하고 있습니다.
Esperion (NASDAQ : ESPR) a annoncé qu'elle publierait ses résultats financiers du premier trimestre 2025 le mardi 6 mai 2025, avant l'ouverture des marchés. La société organisera une webconférence à 8h00 ET pour discuter des résultats et fournir des mises à jour commerciales.
Esperion est une société biopharmaceutique en phase commerciale qui développe et commercialise des médicaments oraux, une fois par jour, non-statines, approuvés par la FDA pour les patients atteints de maladies cardiovasculaires et présentant un taux élevé de LDL-C. Leurs médicaments sont soutenus par l'étude CLEAR Cardiovascular Outcomes Trial, qui a inclus près de 14 000 patients.
La société fait également progresser son programme de nouvelle génération axé sur les inhibiteurs de l'ATP citrate lyase (ACLYi), en utilisant de nouvelles connaissances sur la structure et la fonction pour concevoir rationnellement des inhibiteurs hautement puissants et spécifiques avec des mécanismes allostériques.
Esperion (NASDAQ: ESPR) hat angekündigt, seine Finanzergebnisse für das erste Quartal 2025 am Dienstag, den 6. Mai 2025, vor Börsenöffnung zu veröffentlichen. Das Unternehmen wird um 8:00 Uhr ET ein Webcast veranstalten, um die Ergebnisse zu besprechen und geschäftliche Updates zu geben.
Esperion ist ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das von der FDA zugelassene orale, einmal täglich einzunehmende Nicht-Statin-Medikamente für Patienten mit Herz-Kreislauf-Erkrankungen und erhöhtem LDL-C entwickelt und vermarktet. Ihre Medikamente werden durch die CLEAR Cardiovascular Outcomes Trial unterstützt, an der fast 14.000 Patienten teilnahmen.
Das Unternehmen treibt zudem sein Next-Generation-Programm voran, das sich auf ATP-Citrat-Lyase-Inhibitoren (ACLYi) konzentriert und neue Erkenntnisse über Struktur und Funktion für das rationale Design hochwirksamer und spezifischer Inhibitoren mit allosterischen Mechanismen nutzt.
- FDA-approved oral, once-daily, non-statin medicines in commercial stage
- Large-scale clinical validation with 14,000-patient CLEAR trial
- Advancing next-generation ACLYi drug development program
- None.
ANN ARBOR, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2025 financial results before the market opens on Tuesday, May 6, 2025.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.
A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When will Esperion (ESPR) release Q1 2025 earnings?
What is the main product focus of Esperion (ESPR)?
How many patients were involved in Esperion's CLEAR Cardiovascular Outcomes Trial?
What is Esperion's next generation drug development program?
